Crizotinib, the first FDA-approved ALK tyrosine kinase inhibitor, received regulatory approval in 2011 and rapidly became the preferred targeted therapy for patients with ALK-positive NSCLC [49]. This evidence concerns the gene ALK and non-small cell lung carcinoma.